Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01C, J01CR) — coverage varies; not interchangeable

  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit

Tazocin · DIN 02170817 · 2g & 250mg · injection Pd-2.25g vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2015-04-27 — choose a marketed DIN from the same-category list.Discontinued 2015-04-27 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2015-04-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2015-04-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tazocin · DIN 02170817 Manufacturer: Pfizer Canada Inc.; listing date 2008-12-03 Health Canada: Cancelled post market since 2015-04-27 · brand TAZOCIN · ATC J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for solution · route Intravenous · ingredients PIPERACILLIN (PIPERACILLIN SODIUM) 2 G/VIAL, TAZOBACTAM (TAZOBACTAM SODIUM) 250 MG/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Tazocin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44170 · Verify on the e-Formulary ↗ (DIN 02170817)

Source record
DIN 02170817: Tazocin Raw flags: sec3=Y, sec3b=Y Item: 081216101; group id 30; item number 0062; lccId None; manufacturer id PFI Source form: Inj Pd-2.25g Vial Pk; strength: 2g & 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170817 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44170
Interchangeable products
Piperacillin & Tazobactam For Injection · DIN 02402068 · $10.1300 Piperacillin & Tazobactam for Injection · DIN 02308444 · $10.1300 Piperacillin & Tazobactam for Injection · DIN 02362619 · $10.1300 Piperacillin and Tazobactam for Inj · DIN 02401312 · $10.1300
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2015-04-27 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Piperacillin and Tazobactam for Injection (sterile piperacillin sodium / tazobactam sodium) is indicated for the treatment of patients with systemic and / or local bacterial infections, caused by piperacillin resistant, piperacillin / tazobactam susceptible, ß-lactamase producing strains of the designated microorganisms in the specified conditions listed below: a) INTRA-ABDOMINAL INFECTIONS Appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin resistant, ß-lactamase producing strains of Escherichia coli or members of the Bacteroides fragilis group. b) SKIN AND SKIN STRUCTURE INFECTIONS Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscess, acute ischemic / diabetic foot infections caused by piperacillin resistant ß-lactamase producing strains of Staphylococcus aureus (not methicillin-resistant strains). c) GYNECOLOGICAL INFECTIONS Postpartum endometritis or pelvic inflammatory disease caused by piperacillin resistant, ß - lactamase producing strains of Escherichia coli. d) COMMUNITY-ACQUIRED LOWER RESPIRATORY TRACT INFECTIONS… https://pdf.hres.ca/dpd_pm/00078136.PDF PM date: DEC 24, 2024 Source product: PIPERACILLIN AND TAZOBACTAM FOR INJECTION; DIN 02362619; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Tazocin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026